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Recently a complement inhibitor, decay-accelerating factor 
(DAF), has been found in association with uncharacterized 
fibers in the extracellular matrix of human dermis. Here we 
show by immunohistochemistry and immunoelectronmi-
croscopy that OAF is on the periphery of elastic fibers, and 
that it appears to be associated with some microfibrillar ele-
ments that cover the fibers. That OAF is a component of 
these micro fibrils is also suggested by studies of lesional skin 
from anetoderma, a disease characterized by destruction of 
elastic fibers. In two patients we found a network of residual 
fine fibers in the dermis that stain with antibodies against 
C omplement activation may playa role in the patho-genesis of many diseases of the skin. In pemphigus vulgaris, direct experimental evidence indicates that complement deposition faci litates detachment of epidermal cells from one another and formation of 
blisters [1 -3]. In other diseases there is an association between the 
appearance of lesions and complement deposition. Of relevance is 
that in inflammatory macular atrophy, a disease characterized by 
loss of elastic fibers, C3 is deposited on the remaining elastic fibers 
and in areas where they have been destroyed [4,5]. 
In normal skin complement activation does not occur, even 
though human serum contains antibodies to both the stratum cor-
neum and elastin [6 - 8] . Elastic fibers can also bind Clq indepen-
dently of antibody recognition [9]. The mechanisms that prevent 
complement-mediated tissue destruction in normal skin have not 
been explained. One possibility is that normal skin contains com-
plement inhibitors, which prevent the amplification of the comple-
ment cascade or the attack by the terminal components. In fact, 
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OAF and fibrillin (one of the proteins known to be present in 
the microfibrils of elastin), but do not stain with antibodies to 
elastin. Western blot analysis of dermal extracts with mono-
clonal antibodies to OAF identified a 67 kOa molecule, 
slightly smaller than membrane OAF, and similar in size to 
soluble OAF found in secretions. It is possible that together 
with vitronectin, an inhibitor of the membrane attack com-
plex recently identified in association with el"stin, OAF pre-
vents damage of elastic fibers by complement.] Invest Derma-
toI91 :511-516, 1988 
monoclonal antibodies to one of these inhibitors, decay-accelerat-
ing factor (DAF), react with fibrillar elements in the extracellular 
matrix of the dermis [10]. In the experiments reported here we 
investigated the nature of these fibrillar elements and characterized 
the molecule in dermis that is recognized by the monoclonal anti-
bodies. 
MATERIALS AND METHODS 
Buffers, Proteins, and Antibodies As buffers we used Dul-
becco's phosphate-buffered saline (PBS); PBSg, PBS with 0.01 M 
glycine and 0.02% azide; PBS/l % bovine serum albumin 
(BSA/0.02% sodium azide (PBS/BSA/AZ); 20 mM Tris/50 mM 
NaCl , pH 7.5 (TBS); and TBS/0.05% Tween-20 (TTBS). 
We purified human erythrocyte DAF from butanol or NP40 
extracts of pooled human erythrocyte stroma, as described [11]. 
Monoclonal anti-human DAF antibodies lA10 (lgG2a) and IIH6 
(IgG1) [12], reacting with different DAF epitopes, and rabbit anti-
DAF antibodies were prepared as in Ref 11. Rabbit anti-DAF anti-
bodies were 1110nospecific, as assessed by immunoblotting with 
crude extracts of human erthrocyte stroma [13]. For controls, we 
used mouse MoAb against Trypal'losonla cruz ; and rabbit antibodies to 
malaria parasites. 
Rabbit anti-elastin antibodies were a gift &om Dr. Barbara Faris 
of Boston University. Sheep anti-human Type I collagen antibodies 
were a gift from Dr. Hinda Kleinman of the National Institutes of 
Health . Anti-fibrillin antibodies [14] were a gift from Dr. Eva Eng-
vall of the La Jolla Cancer Research Foundation. Protein A-gold 
was purchased from Janssen (Beerse, Belgium). 
Other reagents for immunolabeling included fluorescein-conju-
gated, affinity-purified goat anti-rabbit and anti-mouse H + L 
chain IgG (Calbiochem Behring); peroxidase-labeled, affinity-pu-
rified goat anti-rabbit H + L chain IgG; and goat anti-mouse H + L 
chain IgG and IgM (Kirkegaard & Perry Laboratories, Inc.). 
Imlnunohistochelnical Studies Normal human skin, keloidal 
skin, and aorta from surgical specimens was snap-frozen at -70 ·C, 
placed in optimal cutting temperature (OCT) compound, and cut at 
-19 · C into 4-Jim sections using a Damon Cryotome (International 
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Equipment Co., Needham Heights, MA). These sections were fixed 
by immersion in acetone/chloroform (1 : 1) for 9 min. The fixed 
and dried sections were washed and overlayered with 1 : 800 dilu-
tions of human OAF MoAb lAl0 or rabbit anti-OAF antibodies in 
PBS/BSA/ AZ. Controls with corresponding amounts of unrelated 
mouse 00Abs or of rabbit antibodies in PBS/BSA/ AZ were used. 
The antl?ody-treated sections were incubated at room temperature 
for 45 mm and, ~fter washing three times in PBS, overlayered with 
FITC or peroxIdase-labeled, affinity-purified second antibodies. 
Sections were then incubated for 45 min and washed. For immuno-
chemical staining u~ing s.heep anti-.human collagen antibody as the 
first antIbody, rabbIt anti-goat antIbody was the second antibody, 
fo llowed by a third step involving incubation with Avidin-Biotin-
Peroxidase Complex (Vectostain ABC Kit). Peroxidase stains were 
developed by immersion for 10 min in 3.3'-diaminobenzidene and 
hydrogen peroxide. Stained sections were counterstained with he-
mat~xylin.' deh~drated, and then mounted. Double labeling with 
rabbIt an~l-elastl?' and .mouse m.onodonal anti-OAF (lAIO) was 
done by II1cubatmg a tIssue sectIon for 45 min with a mixture of 
both antibodies. The second antibody consisted of a mixture of 
rhoda~ine goat anti-rabbit IgG and FlTC goat anti-mouse IgG. 
SectIons of normal and abnormal skin from two patients with 
anetoderma were studied using the above techniques. Antibodies 
tested included rabbit anti-OAF, rabbit anti-elastin, and mouse anti-
fibrillin MoAb and the control antibodies, noted above. 
Immunogold Labeling Fresh tissue was initially frozen at 
-70 · C and cut in 5 J.tm sections. The sections were then placed in 
acetone/chloroform for 8 min and washed with PBSg. Sections 
~ere ne~t incubated for 20 min in PBSg with 0.1 % gelatin and 
nnsed WIth PBSg. They were Incubated with antibody (rabbit anti-
OAF and rabbit anti-malaria diluted in PBSg) at 37·C for 2 h. The 
slides were then incubated with Protein A-gold diluted in PBSg for 
1.5 hat 37 · C. Following seven washes in PBSg and three washes in 
PBS, sections were removed from the slides by razor blade, put in 
separate Eppendorf tubes (six sections for each dilution/Eppendorf 
tube), and fixed with 2% glutaraldehyde in O.1M sodium cacody-
late buffer for 5 min. The sections were pelleted in a microfuge and 
further processed for standard transmission electron microscopy. 
Preparation of Skin Extracts 2 X 0.5 cm skin biopsy specimens 
were tnmmed to the bottom of the dermis and incubated in 1M 
NaCI with protease inhibitors [2 mM phenyl methyl sulfonyl fluo-
ride (PMSF) , 3roM EOTA, 1 roM pepstatin , 20 mM iodoacetamide, 
10 ,ug/ml soybean trypsin inhibitor, 100 ,u/mlleupeptin] for 48 h. 
Ouring this incubation, the epidermis and dermis separa ted from 
one another. Epidermis and dermis were separately washed, minced 
into 1 mm portions with a scalpel, and washed further by centrifu-
gation. Tissue samples were placed in 1 % Nonidet P-40 (NP40), 
2 mM PMSF, 3 mM EOTA, 1 mM pepstatin, 20 mM iodoaceta-
mide, PBS, pH 7.2, and incubated for 1 hat 3rc. Samples were 
centrifuged and supernatants used for affinity purification of OAF. 
Affinity Purification ofDAF from Skin Extracts lAlO anti-
DAF monoclonal antibody was coupled to CNBr-Sepharose (Phar-
macia) according to the manufacturer's instructions. lA 1 O-Sephar-
ose beads were incubated with NP-40 extracts of dermis (1 J.tl beads 
per 500,u1 extract) for 1 hat 3rc. The beads were washed exten-
sively in PBS and the bound OAF molecules were eluted by incuba-
tion for 10 min at 95 · C with 50,111 sample buffer consisting of 5% 
SDS, 125 mM Tris-HCI, pH 6.8, 10% glycerol, 0.01 % brom-
phenol blue. The eluates were removed and used for subsequent 
SOS-PAGE and W estern blot analysis. 
SDS-PAGE and Western Blotting SOS-PAGE was conducted 
on 6% gels under nonreducing conditions. Electrophoresed pro-
teins were transferred to nitrocellulose paper usin g a transblot appa-
ratus. After blocking with whole milk, nitrocel lulose strips were 
incubated at 20 · C for 1 h with 125I-labeled IIH6 anti-OAF mAb or 
control MoAb. The strips were washed and subjected to radioautog-
raphy. 
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RESULTS 
Location .of DAF i:n H~man Dermis MoA~ 1AlO and poly_ 
clonal anti-OAF antIbodIes reacted WIth fibers 111 the dermis that 
re~emb le~ the p.attern .of el~stic fibers seen in similar sections stained 
With antl-e1astlll alltlbodles . Three types of elastic fibers wer 
stained: clastic, thicker fibers located in the reticular dermis (Fie 
lA,B); e1aunin, horizontally oriented fibers in the upper dennis (1).O~ 
shown); and. oxytalan, vertica!ly ~riente? fibers . jl~ the pa~illary 
(upper) dermIS (FIg 1e,D). AntlbodJes aga1l1st fibnlhn, the ITIlcrofi_ 
bnllar glycoprotein that coats elastin, gave patterns similar to thos 
seen with anti-OAF and anti-elastin antibodies (not shown). Con~ 
troIs stained with anti-malaria (Fig lE) and anti-trypanosoma anti_ 
b~dies were .negati~e (not ~hown). Oouble labeling experiments 
WIth antIbodies agall1st elastll1 and OAF confirmed binding of bOth 
antibodies to the same elastic fibers (not shown). Anti-coll agen I 
antibodIes showed a diffuse staining pattern, very distinct from that 
observed with anti-OAF or anti-elastin antibodies. In addition 
there was positive staining.for OAF on the lumina l surface of epi~ 
thehum and clfcumferentlally near the basa l lamina of eccrin~ 
glan?s andducts, as previ.ous ly demonstrated [lOJ, and on anchoring; 
elas ti C fibnl s found outSIde of hair fo il ides (data not shown). Ke, 
loids, which consist of type I coll agen, showed no OAF staining. 
Human aorta clastic fibers did not stain with antibod,ies to DAF. 
Immunogold Labeling of DAF in the Dermis Electron mi, 
CTOSCOpy usil~g immunogold-labeling revealed strong binding of 
antI-OAF antibody to the surface of elastic fibers, with some labe], 
ing of the microfibrils, especially in areas in close proximity to the 
elast ic fibers (Fig 2). Collagen and background labeling was mini, 
mal. Labeling was not seen with the nonimmune control antibody. 
Immunoperoxidase Staining of Anetoderma Anetoderma is a 
skin condition associated with a loss of elastic fibers, and the pres-
ence of res idual network of thin fibril s of unknown composition. As 
shown in Fig 3A, the characteristic thicker elastic fibers were not 
visualized in skin from lesions of anetoderma stained with either 
anti-elastin or anti-OAF antibodies. Only small remnants of elastic 
fibers can be seen in Fig 3A . However, anti-OAF antibodies did 
show a loose network of fibril s in the dermis (Fig 3B). A similar 
pattern was seen with antibodies to fibrillin (Fig 3C). Nonlesional 
skin showed a normal staining pattern for elastin, OAF, and fibrillin 
(cf. Fig 1). No staining was seen with control antibodies. 
Structure of OAF in Dermis By Western blot analysis, using the 
125-I-IlH6 OAF monoclonal antibody, we detected a 67 kOa band 
in the dermal extracts. The molecular weight is slightly lower than 
that ofDAF iso lated from the membrane of human red cells (Fig 4). 
DISCUSSION 
The main finding of this paper is that OAF is closely associated with 
elastic fibers in human dermis as shown by li ght and electronmicro-
scopy. OAF was also found on the anchoring elastic fibrils which 
surround the hair fo llicles, ~nd on the luminal surface of epithelial 
cell s and in a circumferential area near the basal lamina of eccrine 
glands and ducts [10] . Western blot analysis of proteins extracted 
from the dermis with nonionic detergents identified a single band of 
67 kOa. T his is equal in size to so luble OAF foulld in plasma, tears, 
urine, sy novial, and cerebrospinal fluids [10] , but sli ghtly smaller 
than the 70 kOa membrane-associated OAF [11 ,15J. The difference 
in size is thought to reflect a deletion in the C-terminal glycolipid 
anchor of membrane DAF and removal of the terminal fatty acids 
rendering the molecule more soluble [1 6,17J. 
Although it cannot be formally excluded that the 67 kOa mole-
cule identified in the extracts of dermis is a contaminant from the 
interstitial fluids, this seems unlikely because the samples were kept 
in sa line for 48 h durill~ the epidermis/dermis sp!itting procedure, 
and afterwards the mlllced fragments of den11ls were carefu lly 
washed before extraction with detergents. It is conceivable, how-
ever, that soluble OAF from the interstitial fluids , either produced 
locally or originating from serum OAF, binds specifically to elastic 
fibers or is incorporated among the associated microfibrils [18 -20J 
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Figure 1. Immunopcroxidasc localization of OAF and elastin in human dermis. Sections and antibodies used for sta ining are as fo llows. A: reticular dermis, 
anti-OAF antibody; B: reticular dermis, anti-elastin antibody; C: papillary dermis, anti-OAF antibody; D: pap illary dermis, anti-elastin antibody; E: reticular 
d ermis, control anti-malaria antibody. The patterns of OAF and elastin sta ining at high power in both the reticular and papillary dermis are similar, while that 
of the contro l shows no staining of elastic fibers in the reticular dermis. Bar : 55 J.l.111 . 
during their extracellular assembly. Of particular re levance to this 
idea is the observation that vitronectin (S-protein) , al1 inhibitor of 
CSb-9, the membrance attack complex of the complement system 
[21], is also associated with microfibrils found on elastic fibers [22]. 
The number of cells in the dermis is small relative to the elastin, and 
thus any detergent-extracted DAF is predominantly that from elas-
tin. The absence of DAF on aortic elastic fibers may indicate that 
microfibri ls in the skin are different from those in the aorta or that 
OAF is inaccessible to aortic microfibrils. 
The electron microscopic studies showed the presence ofDAF on 
some of the microfibril s, especially on their portions that are in close 
proximity to the elastic fibers. The DAF may indeed be part of the 
fami ly of microfibrillar proteins covering elastic fibers is also sup-
ported by the study of the skin of two patients with anetoderma, a 
disease characterized by the destruction of elastic fibers [23] in the 
dermis (Fig 3A) . The pattern of OAF staining in the skin of these 
patien ts was anomalous. Instead of revealing the thick bundles on 
elas tic fibers, anti-OAF sta ined a loose network of this fibrils (Fig 
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Figure 2. Immunogold labeling of DAF on clastic fibers in the dermis. Acetone-chloroform-fixed 5-I(m thick sections of human skin were immullogold-
labe led using anti -DAF antibodies, as described in the Materials and Methods section. The label for DAF was found located over the surface of the elastic fibers 
and with less density along some o( the microfibril s. Bar: 0. 1 f.lm. 
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Figure 3. immul1opcroxidase localization of elastin in lcsional skin from an 
anetodcrma paticnt. Sections of lesional skin werc stai ncd with anti-elastin 
(A), anti-OAF (B), or antifibrillin (C) antibodies. Lcsional skin stained with 
antielastin antibody shows a few areas of fragmented elastin (arrow/read) and 
countersta ining of fibroblasts (arrow). Lesional skin shows microfibrils stain-
ing with anti-OAF and anti-fibrillin in a similar pattern (arrows). Bar: 55 11m. 
3B). When other sections were stained with monoclonal antibodies 
to fibrillin, a protein known to be part of microfibrils (14J , a very 
similar pattern was observed (Fig 3C). The most likely interpreta-
tion of these findings is that the primary lesion in anetoderma in-
volves the destruction or lack of synthesis of elastin , but that the 
associated microJibrijs are either not affected or are resynthesized. 
However, further studies are necessary to demonstrate that the net-
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Figure 4. Immunoblotting ofNP40 soluble proteins from human dermis. 
Soluble proteins from dermis were extracted with 1 % NP40, affinity puri-
fied on lA 10-sephadex beads, and resolved by electrophcresis on a 6% 
polyacrylamide gel. After transferring to nitrocellulose, proteins were 
treated with 125-i-IIH6. Purified erythrocyte membrane OAF has a molec-
ul ar weight of 70 kOa (A); dermal OAF appears at 67 KOa (B). 
work of thin fibrils which contain DAF and fibrillin in the dermis of 
anetoderma patients is indeed structurally analogous to the microfi-
brils associated with the elastic fibers in normal skin . 
The function of DAF on the elastic fibers is not known. When 
DAF is in association with cell membranes, it prevents the assembly 
[10] and en hances decay [15,24] of the amplification enzymes of the 
complement cascade on autolo gous cells, thereby inhibiting subse-
quent deposition of C3b and membrane damage. DAF may have an 
identical function on elastic fibers. In fact, vitronectin, another 
complement inhibitor, is also found on elastic fibers [22]. Together, 
DAF and vitronectin could control the early and late stages of com-
plement activation, and prevent damage to elastin fo llowing the 
deposition of immune complexes in neighboring sites or by autoan-
tibodies to elastin , such as those found in most normal human sera 
[6- 8]. It is also possible that DAF has other functions, and that its 
role in ski n is unrelated to its function as a complem.ent inhibitor. 
We I"allk [wolla GIIII/per for excel/WI assislallce wit" electro II microscopy alld Roger 
Rose for "elp ill II/alllrscripl preparatiorl. 
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